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Plasma proteome profiling discovers novel proteins
associated with non-alcoholic fatty liver disease
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Sophia Doll1,2, Peter V Treit2, Jens J Holst3,4 , Filip K Knop4,6,8, Tina Vilsbøll6,8, Anders Junker6,8,
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Abstract
Non-alcoholic fatty liver disease (NAFLD) affects 25% of the popu-
lation and can progress to cirrhosis with limited treatment
options. As the liver secretes most of the blood plasma proteins,
liver disease may affect the plasma proteome. Plasma proteome
profiling of 48 patients with and without cirrhosis or NAFLD
revealed six statistically significantly changing proteins (ALDOB,
APOM, LGALS3BP, PIGR, VTN, and AFM), two of which are already
linked to liver disease. Polymeric immunoglobulin receptor (PIGR)
was significantly elevated in both cohorts by 170% in NAFLD and
298% in cirrhosis and was further validated in mouse models.
Furthermore, a global correlation map of clinical and proteomic
data strongly associated DPP4, ANPEP, TGFBI, PIGR, and APOE with
NAFLD and cirrhosis. The prominent diabetic drug target DPP4 is
an aminopeptidase like ANPEP, ENPEP, and LAP3, all of which are
up-regulated in the human or mouse data. Furthermore, ANPEP
and TGFBI have potential roles in extracellular matrix remodeling
in fibrosis. Thus, plasma proteome profiling can identify potential
biomarkers and drug targets in liver disease.
Keywords biomarker discovery; mass spectrometry; NAFLD; NASH; plasma
proteome profiling
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common liver
disease with an estimated prevalence of 25% in the general popula-
tion of Western and Asian countries (Bellentani et al, 2010; Fan
et al, 2017). NAFLD has become an enormous clinical and economic
burden with annual medical costs of over $100 billion in the United
States alone and is projected to keep growing in parallel with the
increasing prevalence of obesity and type 2 diabetes (T2D)
(Younossi et al, 2016). Unfortunately, progression is usually asymp-
tomatic and only manifests when patients develop end-stage liver
disease, which has limited treatment options. Although there is
promising activity in the development of small-molecule drugs
(Cassidy & Syed, 2016), there is currently no Food and Drug Admin-
istration (FDA)-approved drug with beneficial effects on clinical
outcomes (Friedman et al, 2018).
NAFLD is defined as fat accumulation in the liver exceeding 5–
10%, measured either by imaging methods or by liver histology after
exclusion of other etiologies, for instance, heavy alcohol consump-
tion and medication-induced steatosis (Kotronen & Yki-Jarvinen,
2008). NAFLD is further categorized histologically into simple steato-
sis and non-alcoholic steatohepatitis (NASH) with or without
fibrosis. Up to 90% of patients with NAFLD have simple steatosis,
with relatively benign prognosis and small risk of progression to
advanced fibrosis and liver-related mortality, but an increased risk of
cardiovascular events (Dyson et al, 2014; Singh et al, 2015).
However, 10–30% of NAFLD patients have NASH, a more severe
form of the disease with hepatocellular injury and hepatic
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inflammation. NASH has a substantial risk of progression to
advanced fibrosis and mortality (Singh et al, 2015). Early detection
of NASH or fibrosis followed by lifestyle or pharmaceutical interven-
tion would therefore be an ideal first step toward reducing future
cirrhosis-related and cardiovascular deaths.
Liver biopsy remains the gold standard for diagnosing NASH
and for staging the severity of fibrosis. However, there are inherent
limitations of liver biopsy, as it is invasive, associated with compli-
cations such as bleeding, and suffers from sampling bias. Therefore,
the field increasingly employs surrogate non-invasive techniques
for the diagnosis of these conditions (Bril & Cusi, 2017). Radio-
graphic techniques for the assessment of steatosis and liver stiffness
include ultrasound, transient elastography (TE, FibroScanTM; Echo-
sens, Paris, France), multiparametric magnetic resonance imaging
(MRI), magnetic resonance elastography (MRE), and magnetic reso-
nance spectroscopy (MRS). TE with controlled attenuation parame-
ter (CAP) accurately quantifies liver steatosis and stiffness in
patients with NAFLD (Mikolasevic et al, 2016), but it does not have
sufficient accuracy to discern between different stages of fibrosis
(Chang et al, 2016). Furthermore, the use of TE in NAFLD has
significant limitations in older patients and those with obesity (body
mass index (BMI) > 35 kg/m2) or type 2 diabetes as the rate of
unreliable measurements is higher in these populations (Dyson
et al, 2014). Even with a large-size (XL) probe for patients with
obesity, there can still be a discordance in comparison with liver
biopsy (Myers et al, 2012) and complementary methods would
surely be beneficial.
Hepatic injury results in release of specific liver enzymes into the
circulation, and these are routinely measured with blood tests. Clas-
sic markers for liver damage include alanine aminotransferase (ALT)
and aspartate aminotransferase (AST). Elevated levels of these
enzymes are often combined with patient data such as age and
platelet count in NAFLD severity indices such as the fibrosis-4 (FIB-
4) index (Sterling et al, 2006) and with biomarkers in the case of fatty
liver index (Bedogni et al, 2006), NAFLD liver fat score (Kotronen
et al, 2009), APRI, NAFLD fibrosis score (Angulo et al, 2007), and
the Enhanced Liver Fibrosis panel (ELF) (Parkes et al, 2011). Among
these tests, ELF is a commercial panel of three markers reflecting the
process of extracellular matrix remodeling and fibrogenesis. This
method has been found to be the most cost-effective non-invasive
method in identifying patients with advanced liver fibrosis (stages 3
and 4) and has been recommended by NICE guideline as a blood test
to screen for advanced liver fibrosis in adults (Glen et al, 2016). Most
of these tests were developed more than a decade ago and comprise
panels of simple clinical and laboratory variables. Furthermore, by
their nature, these markers detect relatively late changes in liver
pathology. Therefore, in the management of NAFLD, there is an
unmet need to develop non-invasive or minimally invasive methods
with better sensitivity and selectivity to detect NASH and fibrosis as
well as to predict the progression of patients at risk.
After the fibrotic state, which is usually non-symptomatic, liver
disease can further progress to cirrhosis and convert normal liver
architecture into structurally abnormal liver nodules (Anthony et al,
1977). It is characterized by multiple severe physiological condi-
tions, such as reduction in protein synthesis, abnormalities in the
coagulation system, and portal hypertension. Different insults, for
instance, viral infection, steatohepatitis, and autoimmune hepatitis,
can all result in liver cirrhosis (Burt et al, 2015). Because of the
serious prognostic implications of cirrhosis, developing risk markers
or predictors of cirrhosis development is of utmost importance.
As a central secretory organ of the human body, the liver
produces the majority of plasma proteins with a direct function in
the circulation, which is why many of the classical biomarkers for
liver dysfunction are in this category. By extension, liver disease is
likely to affect the blood plasma proteome. Mass spectrometry (MS)-
based proteomics is the technology of choice to analyze proteins in a
systematic and systems-wide fashion. It has undergone persistent
innovations in terms of sample preparation, instrumentation, acqui-
sition methods, and computational analysis and has contributed to
many breakthroughs in basic research over the last decades
(Aebersold & Mann, 2003, 2016; Altelaar et al, 2013; Richards et al,
2015). Today, it clearly has the potential to facilitate disease-related
biomarker discovery in an unbiased and non-hypothesis-driven
manner (Geyer et al, 2017). Our group has recently developed an
automated, rapid, and robust shotgun proteomics pipeline that
allows the streamlined analysis of several hundred plasma proteins,
a technology known as “plasma proteome profiling” (Geyer et al,
2016a). It requires only one microliter of plasma and features high
reproducibility and low variability. So far we have applied this tech-
nology to study the effects of sustained weight loss on the human
plasma proteome and to rigorously assess the quality of plasma
samples (Geyer et al, 2016b; preprint: Geyer et al, 2018).
In this study, we employed and augmented plasma proteome
profiling with a recently introduced data acquisition method termed
“BoxCar” which covers the proteome with about tenfold higher
dynamic range (Meier et al, 2018). We successfully applied this
technology to identify new biomarker candidates for non-alcoholic
fatty liver disease.
Results
Study design and assessment of the plasma proteome analysis
As the plasma proteomics pipeline has not yet been applied to liver
disease, we first set out to study a phenotype for which the effects
should be very drastic. Liver cirrhosis is a more severe condition
than NAFLD and a common end-stage of most types of chronic liver
diseases. As the liver has then undergone substantial changes in
structure and function irrespective of disease etiologies, its analysis
should form a basis for our general understanding of the effects of
liver damage on the plasma proteome profile.
We first chose a cohort of ten non-diabetic patients with cirrhosis
(cirrhosis-cohort) to compare them against ten age-, sex-, and BMI-
matched healthy controls as well as against eight matched individu-
als with T2D and no liver disease (Junker et al, 2015; Fig 1A).
However, our main goal was to investigate the changes in the
plasma proteome in patients with NAFLD before progression to
cirrhosis. As NAFLD is highly associated with obesity and T2D, we
included both subtypes for separate comparisons (Junker et al,
2016; Fig 1A). The first cohort consisted of ten obese patients with
NAFLD and normal glucose tolerance (NGT) (NAFLD-cohort 1), and
the second included ten patients with both NAFLD and T2D
(NAFLD-cohort 2). These cohorts were compared to the matched
controls without NAFLD. The average duration of diabetes was
50 months. The cirrhosis and NAFLD studies had a total of 48
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participants (24 females) with a mean age of 57 years and a mean
BMI of 28 kg/m2 (Dataset EV1).
We improved our previously described plasma proteome profil-
ing pipeline (Geyer et al, 2016a) by deep libraries in combination
with a new acquisition method termed BoxCar (Meier et al, 2018).
This method results in a tenfold increased dynamic range of peptide
signals due to equalized filling pattern of the Orbitrap mass
analyzer. The library consists of pooled and depleted plasma
samples—including from patients with liver diseases (see Materials
and Methods)—that were separated at the peptide level into 24 frac-
tions. This deep plasma library consisted of in total 2,081 proteins.
The study samples were then measured without depletion, but with
BoxCar scans and in technical triplicates, resulting in about 150 LC-
MS/MS datasets (Fig 1B). We quantified on average 503 proteins
per individual (684 in total, of which 3 by single peptide) (Fig 1C),
with MS signals that spanned an abundance range of six orders of
magnitude (Fig 1C and D). To investigate the quality of the study
samples in terms of consistency of collection and handling, we used
our recently developed quality marker panels for coagulation and
erythrocyte contamination (Geyer et al, 2016a; preprint: Geyer
et al, 2018). No outliers of these marker indices were found based
on global protein abundance profiles, indicating that the samples
were of high quality and that changes in plasma proteins should be
due to disease-related pathological disturbances (Fig 1E). We
further analyzed the reproducibility of the measurements by calcu-
lating the coefficients of variation (CVs) within triplicate
measurements and found that 272 proteins had a median CV below
20% (Fig 1F).
Plasma proteome profiling of patients with liver cirrhosis
We first compared the plasma proteome profiles of patients with
liver cirrhosis to that of the two control groups (10 matched healthy
controls and 8 individuals with only T2D but no liver disease). This
revealed a dramatic shift in the quantitative proteome composition,
reflected by 57 significantly differentially abundant proteins (Stu-
dent’s t-test, P < 0.01, permutation-based FDR < 0.05), of which 31
proteins were up-regulated and 26 down-regulated (Fig 2A).
The down-regulated proteins include several classes with a direct
function in the bloodstream, and almost all of them are produced in
the liver. One of the classes contained proteins regulating blood
coagulation and fibrinolysis, for instance, prothrombin (F2), vitamin
K-dependent protein C and S (PROC, PROS1), alpha-2-antiplasmin
(SERPINF2), antithrombin-III (SERPINC1), kallikrein (KLKB1),
heparin cofactor II (SERPIND1), and carboxypeptidase (CPB2)
(Fig 2B). This reflects the central role of the liver in hemostasis, in
which most clotting and anticoagulation factors are synthesized by
parenchymal cells that are also involved in the clearance of acti-
vated products (Palta et al, 2014). The prominent 12–30% abun-
dance changes of these proteins in the plasma proteome (Fig 2C)
are likely to underlie the well-known disturbances of the coagula-
tion system associated with cirrhosis and affecting the prolonged
A
B
C D
E F
Figure 1. Design and quality control of the human study.
A In total, 48 participants from three sub-studies of either NAFLD or cirrhosis with the indicated numbers of patients were included in this study.
B Fasting plasma was collected and distributed into a 96-well plate for proteomic analysis. Proteins were denaturized, reduced, alkylated, and digested using the
automated plasma proteome profiling pipeline, and purified peptides were analyzed in triplicate measurements in a randomization manner by LC-MS/MS. The
resulting 144 raw files were analyzed together with 168 library files by the MaxQuant and Perseus software programs.
C Numbers of quantified proteins in the triplicate measurements.
D Dynamic range of quantified proteins (LFQ, label-free quantitation values).
E Assessment of study quality by analyzing erythrocyte-specific proteins (red circles) and coagulation markers (blue circles). HBA, HBB, HBD: hemoglobin subunits alpha,
beta, delta; FGA, FGB, FGG: fibrinogen chains alpha, beta, gamma.
F Assessment of quantitation accuracy of the LC-MS/MS instrumentation by the number of proteins with a coefficient of variation (CV) below 30, 20, or 10%,
respectively, within three technical replicates.
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bleeding time and increased thrombosis risk in these patients. A
second class consisted of carrier proteins such as apolipoprotein M
(APOM), apolipoprotein C1 (APOC1), and clusterin (CLU), which
play important roles in cholesterol metabolism and are likely to be
associated with cirrhosis-related dyslipidemia due to reduced liver
biosynthesis capacity (Chrostek et al, 2014). In addition, we found
important changes in proteins associated with hormone and vitamin
transportation such as retinol-binding protein (RBP4), transthyretin
(TTR), and vitamin D-binding protein (GC). A final class of proteins
are components of the complement system such as complement
component 6 (C6), complement factor H-related protein 3 (CFHR3),
and complement C1q tumor necrosis factor-related protein 3
(C1QTNF3) (Fig 2B). Members of the latter two classes were down-
regulated substantially, reflecting severe damage to liver function in
cirrhosis (Dataset EV1).
The majority of the up-regulated proteins are involved in
immune system regulation and inflammation such as complement
component C7 (C7), immunoglobulin chains (immunoglobulin
heavy variable 5–51, immunoglobulin J chain, and immunoglobulin
heavy constant mu), polymeric immunoglobulin receptor (PIGR),
vascular cell adhesion protein 1 (VCAM1), alpha-2 macroglobulin
(A2M), and alpha-1-antitrypsin (SERPINA1). Among these proteins,
A2M is an established marker of liver fibrosis (Naveau et al, 1994)
and already incorporated into biomarker blood tests, for example,
the SteatoTest (Poynard et al, 2005) and FibroTest (Imbert-Bismut
et al, 2001). In our study, A2M showed a 54% up-regulation in
patients with cirrhosis.
To investigate the tissue origin of the up-regulated and down-
regulated proteins, we used the data and annotation of the Human
Protein Atlas (HPA) (Kampf et al, 2014). Of note, 77% of the down-
regulated proteins are classified as “liver-specific” with different
degrees of enrichment in the liver relative to the rest of the body
(see Materials and Methods). In stark contrast, only one of the 31
up-regulated proteins was annotated as liver-specific. This indicates
that down-regulation of liver proteins is a reflection of impaired
hepatic protein synthesis and secretion in patients with cirrhosis,
whereas up-regulation represents a systemic response of the body to
cirrhosis (Fig 2A and B). We conclude that liver cirrhosis is clearly
reflected in the plasma proteome profiles of patients through
changes in abundance of proteins originated from the diseased
A
B
C
Figure 2. Reduced protein production and increased immunological
response in cirrhotic liver.
A Volcano plot of statistical significance against log2-fold change between
the cirrhosis group (N = 10) and non-NAFLD group (N = 18), showing
significantly differentially expressed proteins shaded in blue and down-
regulated liver-specific proteins color-coded according to the classification
of Human Protein Atlas (HPA). Significance was defined by independent
two-sample t-test (two-sided) corrected by permutation-based FDR of 0.05.
The percentage of down- and up-regulated “liver-specific” proteins is
indicated.
B Hierarchical clustering of significantly expressed proteins between the
cirrhosis group and non-NAFLD group. Intensities of proteins were log2-
transformed and Z-scored to normalize across individuals. Proteins involved
in different biological processes or belonging to different classes are
indicated by color.
C Violin plot of mean fold changes for down- and up-regulated proteins. The
fold changes of down-regulated proteins were further calculated separately
for the three protein classes indicated in panel B.
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organ as well as specific biological processes that are directly related
to the disease phenotype.
Plasma proteins highly associated with NAFLD
Having revealed proteome changes in plasma of patients with
cirrhosis, we next investigated if the same proteins were affected in
milder forms of liver disease. Our long-term motivation is to help
improve detection of NAFLD, which has proved to be challenging,
especially in relation to the identification of the subsets of patients
who will progress. NAFLD is very heterogeneous and is highly asso-
ciated with obesity and T2D. The prevalence of ultrasonographic
NAFLD in patients with T2D reaches 70% (Leite et al, 2009), much
higher than the 25% of the general population with this diagnosis
(Bellentani et al, 2010). The presence of T2D is an independent
predictor of NASH and advanced fibrosis in NAFLD and vice versa
(Williams et al, 2013; Bazick et al, 2015). Based on these findings,
we decided to analyze our two NAFLD cohorts for common and
potentially separate protein markers.
Our analyses showed a 186% increase of the polymeric
immunoglobulin receptor (PIGR), a 341% increase of fructose-
bisphosphate aldolase B (ALDOB), and a 22% increase of vitro-
nectin (VTN) in NAFLD patients with NGT (NAFLD-cohort 1)
compared with healthy controls (P < 0.001, Fig 3A and B).
Immunoglobulin heavy constant delta (IGHD) was down-regulated
in NAFLD patients by 67%; however, it was not significant in an
up-front one-way ANOVA across all five experimental groups and
was therefore excluded from this panel (Table EV1).
Previous studies have found up-regulation of immunoglobulin A
in patients with NAFLD (Inamine & Schnabl, 2018), and this has
been proposed as a biomarker of changes in the gut microbiota. No
previous evidence has associated NAFLD with immunoglobulin G
(IgG) or M (IgM), and none of the included patients had serum
immunoglobulins outside the normal range. In accordance with the
increased levels of PIGR in patients with NAFLD, we also observed
up-regulated immunoglobulin chains in cirrhosis, among which
most are derived from IgA, IgM, and IgG. These indicate an elevated
immunological response in patients with NAFLD and cirrhosis.
In the NAFLD-cohort 2, we found statistically significant
increases in the levels of PIGR by 157%, galectin-3 binding protein
(LGALS3BP) by 102%, and AFM by 58% (Fig 3C and D). APOM was
significantly decreased by 25%. Like IGHD, IgGFc binding protein
(FCGBP) was also statistically different between disease and control
groups but was excluded from the panel due to insignificance in the
one-way ANOVA (Table EV1). This associates a panel of six
proteins, ALDOB, PIGR, VTN, LGALS3BP, AFM, and APOM, with
NAFLD. At least one of them, PIGR, associated with NAFLD inde-
pendently of the glucose tolerance.
AFM and LGALS3BP have already been suggested as potential
markers for NAFLD (Bell et al, 2010; Wood et al, 2017), providing a
positive control. AFM is a human vitamin E-binding protein in
plasma that is primarily expressed in the liver and secreted into the
circulation. It is strongly associated with components of the meta-
bolic syndrome (Dieplinger & Dieplinger, 2015), NAFLD, and alco-
holic liver disease (ALD) (Bell et al, 2010; Liu et al, 2011; Neuman
et al, 2014). LGALS3BP, which was up-regulated in NAFLD and
T2D, is a candidate biomarker for hepatitis C-related fibrosis and
cirrhosis (Cheung et al, 2010). Interestingly, galectin-3, the ligand of
LGALS3BP, is likewise associated with fibrosis in diverse tissues, for
instance, kidney, lung, liver, and heart (Li et al, 2014). Its critical
role in fibrosis has led to ongoing studies to develop galectin-3
targeted anti-fibrotic drugs. An inhibitor targeting galectin-3, GR-
MD-02, is currently entering phase III trials for NASH and thus may
lead to a first therapy for the treatment of fatty liver disease with
cirrhosis (Henderson et al, 2006; Harrison et al, 2016). The relation
between galectin-3 and LGALS3BP in the context of fibrogenesis
remains to be investigated.
We next asked if any of the NAFLD-associated plasma proteins
were also altered in the plasma proteome of cirrhosis patients. This
was the case for three of the six proteins, which changed also in
NAFLD: PIGR (298%), LGALS3BP (170%), and APOM (21%)
(Fig EV1A and B). Interestingly, the level of PIGR was up-regulated
in all three cohorts and 128% higher in the cirrhosis group
compared to NAFLD, consistent with the notion that increased PIGR
levels may be a novel marker of disease progression (Fig EV1C).
LGALS3BP is also more strongly up-regulated in cirrhosis. The fact
that ALDOB, the protein with the largest fold change in NAFLD,
showed no difference in cirrhosis may be due to the impaired
protein synthesis and secretion that was apparent in the cirrhotic
liver (Fig EV1D).
Global correlation map reveals a panel of five plasma proteins
correlated with liver enzymes
Routine blood tests provide evidence for abnormalities in the
liver, for example, inflammation and hepatocyte cell death. The
most commonly tested liver enzymes are ALT, AST, alkaline
phosphatase (ALP), and gamma-glutamyl transferase (GGT). Note
that levels of these enzymes do not necessarily reflect liver
function but rather liver damage. To evaluate if the plasma
concentration of liver enzymes was associated with other
proteins, we employed global correlation analysis of the plasma
proteome (Wewer Albrechtsen et al, 2018). Filtering for a quanti-
tative data completeness for at least 70%, pairwise correlation of
the liver enzymes and the quantified proteins resulted in a data
matrix with 431 protein levels and 21 clinical parameters. Corre-
lating all variables with each other followed by hierarchical clus-
tering led to a global correlation map containing about 100,000
Pearson correlation coefficients, with clearly apparent clusters of
co-varying proteins and variables (Fig 4A). Strikingly, one of
these groups contained all the above-mentioned liver enzymes, as
well as five further proteins quantified by plasma proteome profil-
ing (Fig 4B). One of these is PIGR, which we had identified as a
protein with the potential to discriminate the non-NAFLD and the
NAFLD groups. The other four are also highly relevant for liver
disease: APOE (apolipoprotein E), dipeptidyl peptidase-4 (DPP4),
TGFBI (transforming growth factor-beta-induced protein ig-h3),
and aminopeptidase N (ANPEP). Individually correlating each of
the four liver enzymes with the plasma proteome confirmed
very high statistical significance, such as that of ALT to ANPEP
(Pearson correlation 0.69; P < 107; Fig EV2A).
After identifying proteins correlating with the established liver
damage marker ALT by the global correlation map, we asked if we
could reproduce these correlations in our very recently published
study on the effect of bariatric surgery in morbidly obese individuals
on the plasma proteome (Wewer Albrechtsen et al, 2018).
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Correlating protein levels with clinically determined ALT levels
across 175 plasma samples confirmed that ALDOB, PIGR, and
ANPEP are statistically significantly correlated, whereas TGFBI is
very close to the threshold (Fig EV3; Dataset EV2).
The global correlation map also showed a significant association
between DPP4 and liver enzymes. Although DPP4 was elevated by
29% in NAFLD patients compared to non-NAFLD controls, this
increase was not statistically significant after correction for multiple
hypothesis testing (P = 0.02). Studies have shown that increased
hepatic expression of DPP4 is associated with NAFLD (Balaban
et al, 2007; Miyazaki et al, 2012; Itou et al, 2013). Hepatocyte-
specific DPP4 overexpression in mice increases body fat and
promotes hepatic steatosis, suggesting that this association is causa-
tive (Baumeier et al, 2017). Taken together with our proteome
A
DB
C
Figure 3. A panel of proteins strongly associated with NAFLD in human cohorts.
A Volcano plot of statistical significance against log2-fold change between NAFLD (N = 10) and controls (N = 10) in NAFLD subtype 1: NAFLD in normal glucose
tolerance. Significance is controlled by P-value (independent two-sample t-test, two-sided) and minimum fold change (s0 parameter in Perseus) indicated by the
cutoff curve, demonstrating significantly up-regulation of PIGR, ALDOB, and VTN.
B Box-and-whisker plot showing the distribution of mass spectrometric intensity values of three proteins in the first NAFLD cohort with median fold changes. The
yellow line is the median, the top and the bottom of the box represent the upper and lower quartile values of the data and the whiskers represent the upper and
lower limits for considering outliers (Q3+1.5*IQR, Q1-1.5*IQR) where IQR is the interquartile range (Q3–Q1). ***, P < 0.001 (independent two-sample t-test, two-sided).
Number of replicates is defined in panel (A).
C Volcano plot of statistical significance against log2-fold change between NAFLD (N = 8) and controls in NAFLD (N = 10) subtype 2: NAFLD in T2D, showing that AFM,
LGALS3BP, and PIGR are significantly up-regulated and APOM significantly down-regulated.
D Box-and-whisker plot showing the distribution of mass spectrometric intensity values of four proteins in the second NAFLD cohort with median fold changes.
Representation of boxes and whiskers is defined as in panel (B). Number of replicates is defined in panel (C).
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profiling results, levels of soluble DPP4 in plasma may represent an
even stronger candidate as an indicator of liver damage. Biologi-
cally, it is a serine protease targeting incretins such as glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide
(GIP). DPP4 inhibitors are widely used as blood glucose-lowering
agents in T2D (Deacon, 2018). DPP4 also plays a role in the degra-
dation of extracellular matrix, the imbalance of which is a hallmark
of liver fibrosis (Itou et al, 2013).
Interestingly, the correlation analysis showed a connection
between liver enzymes, TGFBI and ANPEP, which are also involved
in the remodeling of extracellular matrix (Bieche et al, 2005).
However, nothing is known about a possible role of TFGBI and
ANPEP in liver disease. The up-regulated levels of the extracellular
matrix protein TGFBI that we observed in these patients could
reflect early scar tissue formation in the liver, which in turn may
induce increased levels of DPP4 and ANPEP.
Investigation of the plasma proteome in a mouse model of
high-fat diet-induced NAFLD
As a MS-based method, plasma proteome profiling does not rely on
specific protein epitopes (unlike most antibodies) and can
generically be applied across species to determine to which degree
the biological responses are similar between them. There are well-
established NAFLD mouse models that are generated by high-fat diet
(HFD), and these are commonly used to study the effect of incretin
agonist treatment for diet-induced obesity. We took advantage of a
NAFLD mouse cohort designed to determine the effects of incretin
agonists—alone and in combination—on improving the metabolic
phenotype. It consisted of mice with mild and severe NAFLD
induced by high-fat diet for either up to two months or more than
six months (Fig 5A). The mice with mild NAFLD were treated with
vehicle for 21 days, while the mice with severe NAFLD were
randomly divided into four groups, treated with either vehicle, GIP
receptor agonist, GLP-1 receptor agonist, or GIP/GLP-1 co-receptor
agonist for 15 days while maintaining a high-fat diet. These mono
and dual receptor agonists have previously been reported to reduce
body weight and hepatic steatosis. The unimolecular dual GIP/GLP-
1 receptor agonist has shown superior efficacy relative to GIP or
GLP-1 receptor agonists in the past (Frias et al, 2017; Jall et al,
2017). Therefore, in our cohorts it is expected to have a larger effect
than the two other treatments, providing four groups of disease
trajectories of mice with different severity of NAFLD. This study
design allows us to investigate the potential of our newly identified
A B
Figure 4. Global correlation map of the plasma proteome and clinical variables in human cohorts.
A Pairwise correlation of proteins and clinical variables over the 48 study participants, resulting in a matrix of correlation coefficients where each variable is compared
to all others. Variables with a high positive correlation to each other will cluster together in groups of red rectangles (high correlations). Negative correlation is
indicated in blue patches.
B The magnified area highlights a cluster of variables that contains the four main clinical measurements for liver diseases (blue names) as well as five proteins, which
were quantified by plasma proteome profiling (black gene names).
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marker candidates to monitor treatment effects of this co-agonist in
NAFLD.
Mice with severe NAFLD exhibited a 27% increase in body weight
compared to mice with mild NAFLD. Upon treatment with GLP-1
mono-agonist or GIP/GLP-1 co-agonist, they lost 19% or 24% of body
weight, respectively (Fig 5B). There was no significant weight loss
upon GIP agonist treatment alone. T-test analysis of the quantitative
changes in the plasma proteome between severe and mild NAFLD
mice resulted in 71 significant hits—40 up-regulated and 31 down-
regulated (Fig 5C–O). Pigr and Aldob, which we had found to be asso-
ciated with NAFLD in the human cohorts, were also highly signifi-
cantly up-regulated upon progression in mice (Fig 5C). Median
plasma levels of Pigr in severe NAFLD mice were 780% higher than
those in mild NAFLD (Fig 5D), an even greater change than in the
human cohorts. While Pigr levels decreased upon treatment, especially
in the GLP-1 and combination treatment, these changes were not
significant. Like Pigr, plasma levels of Aldob are drastically increased
in NAFLD compared to mild NAFLD (830%, Fig 5E). These increases
were mostly reversed upon treatment by GLP-1 and GIP/GLP-1 recep-
tor agonist (down-regulation by 62 and 72%, respectively). Sord (sor-
bitol dehydrogenase), another enzyme involved in fructose
metabolism, followed a very similar pattern trajectory (Fig 5F).
The plasma levels of three proteins that are involved in the acute
phase reaction increased strongly upon progression from mild to
severe NAFLD: Saa1 (serum amyloid A-1 protein) by 3,250%, Apcs
(serum amyloid P-component) by 440%, and Orm2 (alpha-1-acid
glycoprotein 2) by 270% (Fig 5G–I). In a weight loss study in
humans, we had previously classified these proteins as members of
a plasma protein panel indicating increased systemic inflammation
(Geyer et al, 2016b). Apcs and Orm2 are primarily expressed in the
liver, and Saa1, which is highly up-regulated in response to
inflammation and tissue injury, is expressed in both liver and
adipose tissue according to the Human Protein Atlas. Given that
inflammation of visceral adipose tissue contributes to the develop-
ment of insulin resistance and steatohepatitis, increased inflamma-
tory factors in the blood in our experimental setup could originate
from both liver and adipose tissue, specifically hepatocytes, adipo-
cytes, and resident or recruited macrophages.
Plasma levels of Dpp4 increased by 322% in abundance in
severe NAFLD (Fig 5J) compared to mild NAFLD. This could be
due to tissue leakage or proactive secretion mediating tissue
crosstalk via circulating factors. A recent study showed that
obesity in mice stimulates hepatocytes to synthesize and secrete
Dpp4, which promotes visceral adipose tissue inflammation and
insulin resistance (Ghorpade et al, 2018). Interestingly, along with
Dpp4, two other aminopeptidases—Lap3 (leucine aminopeptidase
3) and Enpep (glutamyl aminopeptidase)—also increased in
severe NAFLD compared to mild NAFLD, by 273 and 327%,
respectively, followed by a decrease upon treatment (Fig 5K and
L). Protein–protein correlation analysis of the entire dataset of 82
mice in our experimental setup (Dataset EV3) reveals that Lap3,
Enpep, and Me1 (NADP-dependent malic enzyme) correlate with
Pigr, Aldob, and Dpp4 (Fig EV4). This is consistent with our
human study, where PIGR, DPP4, and ANPEP co-vary with the
four classic liver enzymes.
We also found that Apoa4, a major component of high-
density lipoprotein and chylomicrons, increased by 30% upon
progressing from mild to severe NAFLD. This was partially
reversed upon GLP-1 receptor agonist and GIP/GLP co-agonist
treatment (21 and 31% decrease, respectively; Fig 5M). Adipo-
nectin negatively correlates with body weight and its plasma
concentration is reduced in patients with NASH (Balmer et al,
2010). We found adiponectin levels decreased by 23% in severe
NAFLD compared to mild NAFLD, followed by increased levels
in the three treatment groups compared to the non-treatment
group (Fig 5N).
Discussion
Currently established protocols in clinical practice for the diagnosis
and follow-up of NAFLD have certain limitations; for instance, they
may not be sufficiently sensitive at early disease stages. MS-based
proteomics technology holds great potential in generating novel
insights into disease mechanism and discovering new biomarkers.
To identify novel proteins associated with NAFLD and to under-
stand the effect of liver cirrhosis on the plasma proteome, we here
analyzed plasma samples of 48 participants with our streamlined
plasma proteomics workflow, enhanced with a novel MS-acquisition
method featuring high sensitivity.
Our results revealed clinically interesting proteome changes in
NAFLD and in cirrhosis, where we found dysregulation of proteins
associated with thrombosis and homeostasis. These findings are the
proteomic reflection of the hemostatic complications of liver
disease, in particular increased risk of bleeding and venous throm-
boembolism in patients with cirrhosis (Yang et al, 2014). Vitamin A
and D deficiency is a common feature in chronic liver disease. We
found proteins involved in hormone and vitamin transportation to
◀ Figure 5. Plasma proteome changes in a HFD-induced NAFLD mouse model.A Mouse cohort design.
B Box-and-whisker plot showing the distribution of log2-intensity values of body weight across five groups: HFD_1-2 m (N = 6), HFD > 6 m (N = 6), GIP (N = 7),
GLP-1 (N = 8), and GLP-1/GIP (N = 6).
C Volcano plot of statistical significance against log2-fold change between mice on > 6 months of HFD and mice on 1–2 months of HFD. Significance is controlled by
FDR-corrected P-value and minimum log2-fold change of 1 indicated by the blue-dotted line, demonstrating that Saa1, Pigr, Aldob, Lap3, Enpep, and Dpp4 are
significantly up-regulated.
D–O Box-and-whisker plot showing the distribution of log2-intensity values of statistical significantly regulated proteins across five groups. Number of replicates is
defined in panel (B). The yellow line is the median, the top and the bottom of the box represent the upper and lower quartile values of the data and the whiskers
represent the upper and lower limits for considering outliers (Q3+1.5*IQR, Q1-1.5*IQR) where IQR is the interquartile range (Q3–Q1).
Data information: Significance was defined by independent t-test (two-sided) followed by Benjamini–Hochberg correction for multiple hypothesis testing with a
significance level of *P < 0.05, **P < 0.01, and ***P < 0.001.
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be altered in patients with cirrhosis, for example, retinol-binding
protein (RBP4) and transthyretin (TTR). Reduced RBP4 levels are in
concordance with a previous study (Bahr et al, 2009). Both RBP4
and TTR are primarily produced in hepatocytes and transport retinol
to peripheral tissues. In the liver, hepatocytes secret RBP4, to enable
retinoid storage in the hepatic stellate cells (HSC), accounting for as
much as 50–60% of the total retinoid present in the body. The insuf-
ficient levels of RBP4 observed by proteomics might therefore
contribute to vitamin A deficiency.
Among the interesting similarities between patients with cirrho-
sis and patients with NAFLD was PIGR, a little studied protein
produced in the GI tract and endothelial cells but also in the liver.
Strikingly, PIGR increased in abundance in all our three cohorts in
line with the severity of liver damage and the up-regulation is most
dramatic in cirrhosis. We further validated this novel finding in a
mouse model of NAFLD induced by high-fat diet. PIGR is a receptor,
which mediates transcytosis of immunoglobulins from the basolat-
eral to the apical surface of the epithelia, facilitating the secretion of
IgA and IgM. PIGR levels also co-varied with AST, ALT, ALP, and
GGT, four clinical liver markers. The inter-individual variation in
plasma PIGR levels in controls was relatively small, much lower
than that in the NAFLD and cirrhosis cohorts. This finding was also
observed in patients with T2D with no liver damage, thus making
PIGR an interesting biomarker candidate for the inclusion in liver
damage tests.
The plasma proteome changed much less in NAFLD than in
cirrhosis and globally the plasma proteome profiles had few signifi-
cant outliers, both in the cohort with normal glucose tolerance and
in the T2D cohort. This presumably reflects the resilience and regen-
erative capacity of the liver and is also in line with the fact that
NAFLD or early cirrhosis is often asymptomatic and clinically diffi-
cult to detect. Circulating RBP4 levels are among the changes that
have been controversially discussed in the literature, with some
studies finding higher levels in NAFLD (Terra et al, 2013) and some
reporting unchanged levels (Zhou et al, 2017). This parallels our
plasma proteome data, in which RBP4 was clearly significant in
cirrhosis but not in the NAFLD sub-groups.
There is increasing awareness of the importance of screening for
the presence of NAFLD, especially in patients with T2D. However,
this requires markers or marker panels that are specific to NAFLD
and ideally also associated with its progression to fibrosis and cirrho-
sis. Our plasma proteome profiling experiments of three cohorts
provide a step in this direction. We identified a panel of six proteins
in the two NAFLD subtypes: three in NAFLD without T2D (PIGR,
ALDOB, and VTN) and four in NAFLD with T2D (PIGR, LGALS3BP,
AFM, and APOM). Of these, AFM and LGALS3BP have been reported
as potential markers for NAFLD (Bell et al, 2010; Wood et al, 2017).
AFM has been closely linked to metabolic syndrome, insulin resis-
tance, NAFLD, and alcoholic liver disease (Bell et al, 2010; Liu et al,
2011; Neuman et al, 2014; Kollerits et al, 2017). LGALS3BP has
already been used to build multi-component classifiers for the
prediction of NAFLD (Wood et al, 2017) and fibrosis in patients with
hepatitis C infection (Cheung et al, 2010). The elevated levels of
LGALS3BP and vitronectin (VTN), another extracellular matrix
(ECM) protein, are likely a reflection of remodeling of the ECM in
liver disease.
ALDOB is a glycolytic enzyme in the fructose catabolism pathway
that also plays a role in gluconeogenesis and lipogenesis. Evidence
from both animal studies and human studies suggests that dietary
added fructose intake when consumed in excess is a principal driver
of NAFLD and its deleterious consequences (DiNicolantonio et al,
2017). We also observed increased plasma ALDOB levels in the
mouse NAFLD model. This increase may be a consequence of cell
damage, as hepatocytes inflamed due to excessive fat accumulation
may leak out ALDOB. Since that is visible already in NAFLD, it may
be more sensitive than the usually measured liver enzymes AST and
ALT.
In our analysis, we also correlated all proteomics and clinical
variables with each other to identify proteins correlating with
known markers for liver diseases under pathophysiological
conditions. In this global correlation analysis, involving close to
100,000 individual correlation coefficients, proteins that are tightly
co-regulated likely share a common origin or (patho)physiological
pathway. Remarkably, in this unbiased analysis, four clinical
markers used in liver disease—ALT, AST, ALP, and GGT—clus-
tered into a single group together with a panel of five proteins of
special interest—PIGR, DPP4, ANPEP, TGFBI, and APOE. Among
these proteins are two enzymes involved in degradation of the
ECM (ANPEP, DPP4) and an ECM protein (TGFBI). This may
again reflect the remodeling of the ECM in the liver, which is part
of the progression to liver fibrosis. Even more interesting, DPP4,
which proteolytically cleaves GLP-1 and GIP, has been reported to
increase in both plasma and liver tissue of NAFLD patients
(Miyazaki et al, 2012; Anoop et al, 2017). DPP4 inhibitors are
also widely used diabetes drugs worldwide. Interestingly, there
are currently clinical trials evaluating the efficacy and safety of
DPP4 inhibitor sitagliptin for the treatment of NAFLD (Fukuhara
et al, 2014) and in steatosis irrespective of diabetes in NASH
(Alam et al, 2018). Taken together with our proteomic data, it
would be interesting to further investigate the potential of circulat-
ing DPP4 levels to serve as prognostic marker for both T2D and
NAFLD. The same may apply for the other four proteins in this
five-protein panel as they also correlate very well with liver
enzymes of hepatic damage. Remarkably, we also observed this
close correlation between DPP4 and PIGR in our mouse dataset,
where we found that two additional aminopeptidases, Lap3 and
Enpep, similarly were increased under NAFLD. Together, our anal-
ysis points to an important relationship between aminopeptidases
and NAFLD.
In conclusion, in this study we found changes in the plasma
proteome of patients with cirrhosis and patients with NAFLD
that are clearly linked to the underlying disease manifestations
and clinical observations. PIGR and ALDOB are in our panel of
six proteins significantly associated with NAFLD and were also
validated in a mouse NAFLD cohort making them interesting
candidates for follow-up studies. PIGR is a particularly promising
protein as its association with NAFLD and liver cirrhosis is
novel, and its levels in plasma are highly correlated with DPP4,
a widely used drug target in the treatment of T2D. This correla-
tion holds true in both human and mouse cohorts. Blocking the
enzymatic function of the other aminopeptidases may have
effects on the fibrotic process in NAFLD progression. To evaluate
the potential and specificity of the above proteins to be
developed or incorporated into liver disease panels, we plan to
perform plasma proteome profiling on larger and more fine-
grained cohorts.
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Materials and Methods
Reagents and Tools table
Reagent/Resource Reference or Source Identifier or Catalog Number
Experimental Models
Blood plasma samples (H. sapiens) (Junker et al, 2015, 2016) N/A
Blood plasma samples (M. musculus) This study N/A
Chemicals, enzymes and other reagents
Isopropanol Sigma Aldrich/Merck Cat # 67-63-0
Formic acid Sigma Aldrich/Merck Cat # 64-18-6
Acetonitrile Sigma Aldrich/Merck Cat # 75-05-8
Pierce Dimethylsulfoxide (DMSO), LC-MS
Grade
Thermos Fisher Scientific 85190
Water, OptimaTM LC/MS Grade Fisher Chemical Cat # W64
25% LC-MS grade ammonia Merck Millipore Cat # 533003
Trifluoroacetic acid Sigma Aldrich/Merck Cat # 76-05-1
Multiple Affinity Removal Column
Human 6
Agilent 5188-5341
Seppro Protein Depletion Sigma Aldrich SEP010
Software
MaxQuant (1.5.8.6) https://maxquant.org/ N/A
Perseus (1.5.50) https://maxquant.net/perseus/ N/A
Jupyter Notebook https://jupyter.org/ N/A
Other
Empore SPE SDB-RPS disk Sigma Aldrich/Merck Cat # 66886-U
96-Well Plates Thermo Fisher Cat # AB-1300
Silicone sealing mat, for 96 well
PCR-plates
Nerbe Plus Cat # 04-090-0000
Reprosil-Pur Basic C18, 1.9 µm Dr. Maisch Gmbh Cat # r119.b9
PicoFrit self-pack columns Pico FRIT Cat # PF360-75-15-N-5
iST’ sample preparation kit PreOmics GmbH Cat # P.O. 00001
ThermoMixer® Eppendorf Cat # 460-0223
Bravo Automated Liquid Handling
Platform
Agilent Cat # G5409A
NanoDropTM One/OneC Microvolume
UV-Vis Spectrophotometer
Thermo Fisher Cat # ND-ONEC-W
Concentrator plus Eppendorf Cat # F-45-48-11
EASY-nLCTM 1200 System Thermo Fisher Cat # LC140
Q ExactiveTM HF Hybrid Quadrupole-
OrbitrapTM Mass Spectrometer
Thermo Fisher Cat # IQLAAEGAAPFALGMBFZ
Q ExactiveTM HF-X Hybrid Quadrupole-
OrbitrapTM Mass Spectrometer
Thermo Fisher Cat # 0726042
Ethical approval
The study protocol was approved by the scientific-ethical committee
of the Capital region of Denmark (H-1-2011-082) and registered
with the Danish Data Protection Agency (2011-41-6410) and
ClinicalTrials.gov (reg. no. NCT01492283). The study was conducted
according to the principles of the Declaration of Helsinki, and
oral and written informed consent was obtained from all partici-
pants.
Study design
Plasma samples, all taken in the fasting state, were derived from two
previously published studies. The details including corresponding
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clinical data and laboratory data are in Junker et al (2016, 2015),
and the groups are briefly described below. Patients had I) normal
glucose tolerance (NGT) and no liver disease, II) NGT and
NAFLD, III) T2D without liver disease, IV) T2D with NAFLD, and
V) cirrhosis. NAFLD was diagnosed based on histology and graded
according to hepatic fat infiltration: no NAFLD (< 5% fat infiltra-
tion), mild (5–33%), moderate (33–66%), and severe (> 66%).
Non-alcoholic steatohepatitis (NASH) and fibrosis were graded
according to the NAFLD activity score. Eight of the 20 patients
with NAFLD also had NASH/fibrosis (all below fibrosis score 5).
Cirrhosis was diagnosed histologically and clinically, based on
signs of decompensation (e.g., ascites).
Individuals with T2D were diagnosed according to World
Health Organization criteria. Exclusion criteria included weekly
alcohol consumption of more than seven units for women and
14 units for men, treatment with steatogenic drugs within
3 months prior to inclusion, anemia, inflammatory bowel disease,
gut resection, increased creatinine (> 150 lmol/l), albuminuria,
or other chronic diseases. Controls were healthy (and matched
with age, BMI, and gender) with no family history of diabetes,
signs of liver disease (based on patient history, biochemical
measurements, and ultrasound assessment), or other chronic
diseases.
Mouse experiments
To induce substantial obesity and NAFLD, we fed 8-week-old male
C57Bl6/J mice (Charles River, River Laboratories, Wilmington, MA,
USA) with a high-fat, high-sugar diet (HFD) comprising 58% kcal
from fat (D12331; Research Diets, New Brunswick, NJ, USA) for
32 weeks. Another 6 male C57Bl6/J mice were maintained on regu-
lar chow diet and switched to HFD for 5 weeks at an age of
34 weeks to induce mild obesity and NAFLD. Mice were single- or
double-housed on a 12:12-h light–dark cycle at 22°C with free access
to water and food. Sample size estimation was done the same as in
the human study (see Study design).
Mouse pharmacology
The synthesis, purification, and characterization of the GLP-1/GIP
co-agonist and the single GLP-1 and GIP mono-agonist controls were
described previously, and the peptides were used without any
further chemical modification or change in formulation (Finan et al,
2013). Whole-body composition (fat and lean mass) was measured
with nuclear magnetic resonance technology (EchoMRI, Houston,
TX, USA). For the treatment study in mice with severe NAFLD, DIO
mice maintained for 32 weeks on HFD and then randomized to
either vehicle, GLP-1, GIP, or GLP-1/GIP treatment according to
body weight and body composition. Mice with mild NAFLD were
fed HFD for 5 weeks and then treated with vehicle for the same time
period as the other mouse groups. Compounds were administered
in a vehicle of PBS (Gibco) and were given by daily subcutaneous
injections at a dose of 10 nmol/kg at a volume of 5 ll per g body
weight for 15 days. The investigators were not blinded to group
allocation during the in vivo experiment. All procedures were
approved by the Animal Use and Care Committee of Bavaria,
Germany, in accordance with the Guide for the Care and Use of
Laboratory Animals.
Methods and Protocols
Plasma sample preparation
All plasma samples were prepared according to the previously
published plasma proteome profiling pipeline on an automated liquid
handling system (Agilent Bravo) in a 96-well plate format (Geyer et al,
2016a). In brief, proteins were denatured, reduced, alkylated, and
digested and peptides purified on StageTips (Kulak et al, 2014) using
reagents from the PreOmics “iST” Kit (P.O. 00001, PreOmics GmbH).
In detail:
1 Transfer of 5 ll of blood plasma sample into an Eppendorf 96-
well plate at 4°C on an Agilent Bravo liquid handling system
(Plasma plate).
2 Make a 1:10 dilution by adding 45 ll of SDC reduction and alkyla-
tion buffer (included in PreOmics “iST” kit) into each well of the
Plasma plate, mix thoroughly by pipetting 50 times up and down
for a volume of 40 ll, and centrifuge the plate up to 300 × g.
3 Pipet 20 ll of tenfold diluted plasma into a new 96-well plate
(Digestion plate).
4 Heat the plate at 95°C for 10 min.
5 Move the Digestion plate to room temperature and cool it down
for 5 min. Meanwhile, prepare fresh trypsin/LysC mix in 0.05
(lg/ll) (total volume calculated by 20 ll per sample, 1:100
micrograms of enzyme to micrograms of protein).
6 Add 20 ll of trypsin/LysC mix into each well to a final volume
of 40 ll.
7 Heat the Digestion plate at 37°C for 4 h (enzymatic digestion).
8 Quench the reaction by adding 40 ll of the PreOmics washing
buffer 1, and mix thoroughly by pipetting 20 times up and down.
9 Prepare 96 StageTips on a home-made 3D-printed centrifugation
block (2-plug SDB-RPS material (thickness 0.5  0.05 mm) in
14-gauge).
10 Transfer 24 ll of the mixture onto the StageTips. Centrifuge the
StageTip block at 1,500 × g for 15 min.
11 Add 150 ll of the PreOmics washing buffer 1 to the StageTips,
and centrifuge at 1,500 × g for 15 min.
12 Add 150 ll of the PreOmics washing buffer 2 to the StageTips,
and centrifuge at 1,500 × g for 15 min.
13 Elute the peptides by adding 60 ll of elution buffer (1% ammo-
nia in 80% acetonitrile), centrifuge at 1,500 × g for 15 min, and
collect peptides in PCR tube-stripes (0.2 ml volume).
14 Concentrate the peptide mixture by Speed-Vac at 60°C under
vacuum for 90 min.
15 Re-suspend the peptide mixture in 40 ll of buffer A* (2%
acetonitrile, 0.1% TFA in ddH2O).
High-pressure liquid chromatography and mass spectrometry
Samples were measured using LC-MS instrumentation consisting of
an EASY-nLC 1200 system coupled to a nano-electrospray ion
source and a Q Exactive HF Orbitrap (all Thermo Fisher Scientific).
Purified peptides were separated on 40-cm HPLC columns (ID:
75 lm; in-house packed into the tip with ReproSil-Pur C18-AQ
1.9 lm resin (Dr. Maisch GmbH)). For each LC-MS/MS analysis,
around 0.5 lg peptides was injected for the 45-min gradients and
1 lg for the fractions of the deep plasma dataset.
Additionally, we established very deep plasma proteome
libraries. We pooled samples from all healthy individuals, NAFLD
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patients, and liver cirrhosis patients separately and depleted the 14
highest abundant plasma proteins by serial depletion with a top6
(Multiple Affinity Removal Column Human 6; Agilent) and top14
depletion kits (Seppro Protein Depletion; Sigma-Aldrich). After
digestion, the peptides were separated by the Spider Fractionator
(Kulak et al, 2017) into 24 fractions. This library was combined
with an additional peptide library that had been established in the
same way in a separate study (Wewer Albrechtsen et al, 2018).
Peptides were loaded in buffer A (0.1% formic acid, 5% DMSO (v/
v)) and eluted with a linear 35-min gradient of 3–30% of buffer B
(0.1% formic acid, 5% DMSO, 80% (v/v) acetonitrile), followed by a 7-
min increase to 75% of buffer B and a 1-min increase to 98% of buffer
B, and a 2-min wash of 98% buffer B at a flow rate of 450 nl/min.
Column temperature was kept at 60°C by a Peltier element containing
an in-house-developed oven. For human plasma, MS spectra were
acquired with a Top15 data-dependent MS/MS scan method (topN
method) for the library and with the BoxCar scan method for study
samples (Meier et al, 2018). The target value for the full scan MS spec-
tra was 3 × 106 charges in the 300–1,650 m/z range with a maximum
injection time of 55 ms and a resolution of 120,000 at m/z 200. Frag-
mentation of precursor ions was performed by higher-energy collisional
dissociation (HCD) with a normalized collision energy of 27 eV. MS/
MS scans were performed at a resolution of 15,000 at m/z 200 with an
automatic gain control (AGC) target value of 5 × 104 and a maximum
injection time of 25 ms. For mouse plasma, MS spectra were acquired
with a data-independent acquisition (DIA) method. The DIA-MS
method consisted of an MS1 scan from 350 to 1,650 m/z range (AGC
target of 3 × 106, maximum injection time of 50 ms) at a resolution of
120,000 and 22 DIA segments (AGC target of 3 × 106, maximum injec-
tion time of 54 ms) at a resolution of 30,000 (Dataset EV3). Normalized
stepped collision energy was set to 25, 27.5, 30, with a default charge
state of 2. The acquisition of samples was randomized to avoid bias.
Data analysis
For human plasma, mass spectrometric raw files were analyzed in
the MaxQuant environment v.1.5.8.6 (Cox & Mann, 2008) employing
the Andromeda search engine (Cox et al, 2011). The MS/MS spectra
were searched against the human UniProt FASTA database (version
201704, 157,510 entries). Enzyme specificity was set to trypsin with
a maximum of 2 missed cleavages, and the search included cysteine
carbamidomethylation as fixed modification and oxidation on
methionine and N-terminal acetylation as variable modifications
with a minimum required peptide length of 7 amino acids. A false
discovery rate (FDR) of 0.01 was set at the peptide and protein
levels. Study samples were analyzed together with our in-house
generated matching library and the “match between runs” algorithm
(Nagaraj et al, 2012). Label-free quantitation (LFQ) was performed
with a minimum ratio count of 2 and normalized in a separate group
from the library raw files (Cox et al, 2014).
After filtering for “reverse”, “only identified by site”, “contami-
nants”, and at least two valid values in any of the three technical
replicates, we came to a dataset containing 684 protein groups
(Dataset EV1, tab 2). We took the median value from the technical
triplicates and further filtered the dataset for 70% data completeness
in at least one experimental group. This resulted in 520 protein
groups with 11% missing values (Dataset EV1, tab 3). We then
replaced the missing values by drawing random samples from a
normal distribution (downshifted mean by 1.8 standard deviation
(SD) and scaled SD (0.3) relative to that of proteome abundance
distribution). This further resulted in a final dataset (Dataset EV1,
tab 4) with which we performed the statistical analysis (except for
global correlation analysis, which we filtered for 70% data
completeness across all samples instead of one sub-group, resulting
in 431 protein groups, without imputation (Dataset EV1, tab 5)).
For mouse plasma, DIA raw data were analyzed with Spectro-
naut Pulsar XTM with an in-house generated spectra library of mouse
plasma that contains 8,899 peptides and 1,458 protein groups
(mouse FASTA UniProt FASTA database version 201806 containing
92,096 entries). Spectronaut Pulsar XTM was used with default
settings for DIA data with the decoy generation set to “mutated”.
Bioinformatic analysis
Bioinformatic analysis was performed in the Perseus platform
(Tyanova et al, 2016) and Python scripts. Two-sample Student’s t-
test was used to determine the significantly changed proteins
between disease and control groups with a permutation-based FDR
of 0.05. For significant hits, minimal fold changes together with P-
values (controlled by the s0 parameter in Perseus) were used with a
permutation-based FDR of 0.05 resulting from an s0 of 0.01. For
mouse plasma analysis, we used scipy.stats.ttest_ind to calculate t-
test probabilities for the means of two independent samples. This
was corrected for an FDR of 0.05 by the Benjamini–Hochberg
method. Results were filtered to have both a significant FDR-
corrected P-value and a minimum log2-fold change of  1.
Shapiro–Wilk test was applied to test normality of each individual
protein across all five groups in the human study, and 75–80% of
proteins are normally distributed. Levene’s test was used to assess
the equality of variances for each individual protein calculated for
two groups in each of the NAFLD sub-cohorts. As a result, 95% of
the proteins have equal variances. All six proteins reported in this
study associated with NAFLD met the assumptions of the tests.
Liver-specific proteins were annotated according to the Human
Protein Atlas, which defines “liver enriched”, “group enriched”, and
“liver enhanced” proteins with at least 500% higher mRNA levels in
liver compared to all other tissues, at least 500% higher mRNA
levels in a group of 2–7 tissues compared to the rest, and at least
500% higher mRNA levels in the liver compared to average levels in
all tissues, respectively.
Fold changes between conditions were calculated as Condition
A/Condition B -1 for protein label-free (LFQ) intensities. The
changes are indicated in percentage (e.g., increased by 62% and
decreased by 27%).
Data availability
The datasets in this study are available in the following databases:
• Proteomic dataset for the human cohorts: PRIDE archive
PXD011839 (Vizcaino et al, 2016) (https://www.ebi.ac.uk/pride/
archive/).
• Proteomic dataset for the mouse model: PRIDE archive PXD012056.
Expanded View for this article is available online.
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